HK Stock Market Move | CARSGEN-B(02171) surged over 8% with impressive clinical data. The temporary halt of the US clinical trial has been lifted by the FDA.

CARSGEN-B (02171) surged over 8%, as of press time, it rose by 8.88% to 5.15 Hong Kong dollars, with a turnover of 162.786 million Hong Kong dollars. On the news front, on November 6, Koji Pharmaceuticals announced that the data of Saikeze (zevoleukin injection), CT071 and CT0590 will be presented in poster form at the 66th American Society of Hematology (ASH) annual meeting, which will be held from December 7 to 10, 2024. The summaries of the above products have already been published on the ASH official website. Among them, the preliminary results of the CT0590 study indicate that the safety of the CT0590 universal CAR-T cell therapy is controllable, while achieving deep and lasting clinical remission. Furthermore, Koji Pharmaceuticals previously announced that the US FDA has lifted the clinical trial suspensions of zevoleukin injection (zevor-cel, CT053, a self-targeting BCMA CAR-T cell product), satri-cel (satri-cel, CT041, a self-targeting Claudin18.2 CAR-T cell product) and CT071 (a self-targeting GPRC5D CAR-T cell product) in the United States. The clinical trial suspensions were related to findings released after the FDA conducted an inspection of the company's clinical production base in Durham, North Carolina in December 2023.